Detail akcie Dogwood Therap Rg online

Business Summary: Dogwood Therapeutics, Inc. is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Dogwood Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased from $4.6M to $31.7M. Higher net loss reflects Biotechnology company segment loss increase from $3.4M to $24.2M. Basic Earnings per Share excluding Extraordinary Items decreased from -$4.83 to -$18.65.